PDGFRA and gastrointestinal stromal tumor: There is little evidence for modification of dosage and administration schedule for sunitinib- and regorafenib-resistant patients, combination of TKIs and local therapy, and treatment of GIST caused by abnormalities other than c-kit or PDGFRA genes.